1
|
Khalil H, Borai A, Dakhakhni M, Bahijri S, Faizo H, Bokhari FF, Ferns G, Mirza AA. Stability and validity of intact parathyroid hormone levels in different sample types and storage conditions. J Clin Lab Anal 2021; 35:e23771. [PMID: 33792964 PMCID: PMC8183913 DOI: 10.1002/jcla.23771] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2021] [Revised: 02/16/2021] [Accepted: 03/16/2021] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Several pre-analytical factors can affect the measurement of intact Parathyroid Hormone (IPTH). In this study, we have investigated the effects of using different types of tubes, time elapsed before separation, and storage conditions over time on the measured values of IPTH. METHOD Blood samples from 30 subjects were collected into plain, SST, and EDTA tubes. All serum and plasma were separated immediately (first set) and after 2 hrs delay (second set). The first set of samples were aliquoted and stored at RT (25°C), at fridge (4°C), and freezer (-20°C). IPTH was measured in all the stored aliquots at 2,4, and 8 days after collection using Architect analyzer. RESULTS Paired T test and ANOVA repeated measures showed no significant difference between IPTH levels in all tubes. The second set of serum and plasma were significantly lower (3.8% and 7.4%, p < 0.001, respectively) when compared to samples measured initially. Serum samples stored at RT were significantly lower (by 45%,59%, and 77%) on days 2,4, and 8 when compared to the initial time (p < 0.001 in all cases). Plasma samples stored at RT, were significantly lower on day 8 after collection, by 30.8% (p < 0.001). These differences would be clinically important. CONCLUSION Plasma IPTH can be stored at RT for up to four days. Both plasma and serum IPTH are not affected by a delay in the separation of up to two h and they can be stored for up to 8 days in a fridge or freezer without any clinically significant changes in their values.
Collapse
Affiliation(s)
- Haitham Khalil
- King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Pathology, King Abdulaziz Medical City, Jeddah, Saudi Arabia.,Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Anwar Borai
- King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Pathology, King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Mohammed Dakhakhni
- King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Pathology, King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Suhad Bahijri
- Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Hala Faizo
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Fawzi F Bokhari
- Academic Affairs, Armed Forces Hospital Administration, Taif, Saudi Arabia
| | - Gordon Ferns
- Division of Medical Education, Brighton and Sussex Medical School, Mayfield House, Brighton, United Kingdom
| | - Ahmed A Mirza
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
| |
Collapse
|
2
|
Abstract
Laboratory biochemical testing is critical to the clinical understanding of bone disorders. Patients with skeletal diseases have underlying themes in their pathophysiology that would be impossible to detect without biochemical assessment of serum and urine minerals, vitamin D, parathyroid hormone, parathyroid hormone-related peptide, and bone turnover markers. Bone disorders are caused by abnormalities in signaling pathways that affect bone formation and resorption. Therapies for common bone diseases were developed in direct response to underlying biochemical abnormalities.
Collapse
Affiliation(s)
- Chee Kian Chew
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, E-18A, 200 1st Street Southwest, Rochester, MN 55905, USA
| | - Bart L Clarke
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, E-18A, 200 1st Street Southwest, Rochester, MN 55905, USA.
| |
Collapse
|
3
|
Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrol Dial Transplant 2013; 28:2260-8. [PMID: 23787544 PMCID: PMC3769981 DOI: 10.1093/ndt/gft227] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Background Chronic kidney disease (CKD) is associated with elevations in serum phosphate, calcium–phosphorus product and bone-specific alkaline phosphatase (BAP), with attendant risks of cardiovascular and bone disorders. Active vitamin D can suppress parathyroid hormone (PTH), but may raise serum calcium and phosphate concentrations. Paricalcitol, a selective vitamin D activator, suppressed PTH in CKD patients (stages 3 and 4) with secondary hyperparathyroidism (SHPT) with minimal changes in calcium and phosphate metabolism. Methods The VITAL study enrolled patients with CKD stages 2–4. We examined the effect and relationship of paricalcitol to calcium and phosphate metabolism and bone markers in a post hoc analysis of VITAL. The study comprised patients with diabetic nephropathy enrolled in a double-blind, placebo-controlled, randomized trial of paricalcitol (1 or 2 μg/day). Urinary and serum calcium and phosphate, serum BAP, and intact PTH (iPTH) concentrations were measured throughout the study. Results Baseline demographics and calcium, phosphate, PTH (49% with iPTH <70 pg/mL), and BAP concentrations were similar between groups. A transient, modest yet significant increase in phosphate was observed for paricalcitol 2 μg/day (+0.29 mg/dL; P < 0.001). Dose-dependent increases in serum and urinary calcium were observed; however, there were few cases of hypercalcemia: one in the 1-μg/day group (1.1%) and three in the 2-μg/day group (3.2%). Significant reductions in BAP were observed that persisted for 60 days after paricalcitol discontinuation (P < 0.001 for combined paricalcitol groups versus placebo). Paricalcitol dose-dependent reductions in iPTH were observed. Paricalcitol in CKD patients (±SHPT) was associated with modest increases in calcium and phosphate. Conclusion Paricalcitol reduces BAP levels, which may be beneficial for reducing vascular calcification. Trial registration Trial is registered with ClinicalTrials.gov, number NCT00421733.
Collapse
Affiliation(s)
- Daniel W Coyne
- Division of Renal Diseases, Washington University School of Medicine, St Louis, MO, USA
| | | | | | | | | |
Collapse
|
4
|
Hanon EA, Sturgeon CM, Lamb EJ. Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. Clin Chem Lab Med 2013; 51:1925-41. [DOI: 10.1515/cclm-2013-0315] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Indexed: 01/01/2023]
|
5
|
New insights on the stability of the parathyroid hormone as assayed by an automated 3rd generation PTH assay. Clin Chim Acta 2012; 413:353-4. [DOI: 10.1016/j.cca.2011.09.034] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2011] [Revised: 09/26/2011] [Accepted: 09/26/2011] [Indexed: 11/19/2022]
|
6
|
La’ulu SL, Roberts WL. Performance characteristics of six intact parathyroid hormone assays. Am J Clin Pathol 2010; 134:930-8. [PMID: 21088157 DOI: 10.1309/ajcplgczr7ipvha7] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
The aim of this study was to evaluate the performance characteristics of 6 intact parathyroid hormone assays: Access 2 (Beckman Coulter, Fullerton, CA), ARCHITECT i2000(SR) (Abbott Diagnostics, Abbott Park, IL), ADVIA Centaur (Siemens Healthcare Diagnostics, Deerfield, IL), Modular E170 (Roche Diagnostics, Indianapolis, IN), IMMULITE 2000 (Siemens Healthcare Diagnostics), and LIAISON (DiaSorin, Stillwater, MN). Sample collection tubes and storage conditions were compared. Imprecision studies were performed using commercial quality control materials. Linearity was assessed using pools prepared from samples. For method comparison, serum and EDTA plasma samples were tested by all methods, and the ARCHITECT was used as the comparison method. Reference intervals were determined using various vitamin D cutoffs. The types of collection tubes and storage conditions are more important for some methods than others. Total coefficients of variation were 10.9% or less. The maximum deviation from the target recovery for linearity ranged from 5.0% to 82.2%. Bland-Altman plots demonstrated percentage biases ranging from -36.3% to 24.4%. The lower limit of the reference interval was not influenced by vitamin D status, whereas the upper reference limit was affected.
Collapse
|
7
|
|
8
|
Parent X, Alenabi F, Brignon P, Souberbielle JC. Conservation du tube primaire sur le site de dialyse en vue du dosage différé de la PTH : quels tubes ? Quelle température ? Nephrol Ther 2009; 5:34-40. [DOI: 10.1016/j.nephro.2008.04.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2007] [Revised: 03/19/2008] [Accepted: 04/19/2008] [Indexed: 11/25/2022]
|
9
|
Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008; 51:987-95. [PMID: 18430500 DOI: 10.1053/j.ajkd.2008.01.017] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2007] [Accepted: 01/30/2008] [Indexed: 11/11/2022]
Abstract
BACKGROUND Previous reports show that parathyroid hormone (PTH) concentrations may vary widely depending on the assay used to assess PTH. In this cross-sectional study, we aim to determine the usefulness of standardizing blood handling for optimal interpretation of PTH in patients with chronic kidney disease. STUDY DESIGN Diagnostic test study. SETTING & PARTICIPANTS Predialysis blood was sampled in 34 long-term hemodialysis patients at a single academic medical center. INDEX TEST PTH was measured by using 6 different automated second-generation assays (Elecsys, Advia Centaur, LIAISON, Immulite, Architect, and Access assays), 3 blood specimen types (serum, EDTA plasma, and citrate plasma), and 2 consecutive days of measurement (after thawing and 18 hours later with samples having been let at room temperature). REFERENCE TEST None. RESULTS A mixed statistical analysis model showed that the nature of the assay (P < 0.001) and nature of the blood sample (P < 0.001) significantly influenced variability in PTH concentrations, whereas day of measurement (day 1 or 2) did not (P = 0.5). Most PTH variability was caused by observations (96.8%), then manufacturer's kit (2.5%), and last, specimen type (0.7%). PTH concentrations measured in citrate plasma were lower with every assay method used than those observed in serum or EDTA plasma. The interaction between manufacturer and specimen type was of moderate statistical significance (P = 0.04). To evaluate the potential clinical consequence of PTH measure variability, we classified patients according to Kidney Disease Outcomes Quality Initiative cutoff values (PTH < 150 pg/mL; PTH, 150 to 300 pg/mL; and PTH > 300 pg/mL). Overall, statistical classification agreement was moderate to high for comparison between assays and high to very high between different blood samples and between days of measurement. However, we found that up to 11 of 34 patients were classified in different categories with some assays (LIAISON versus Architect) and up to 7 of 34 in different categories with different blood specimen type (citrate plasma versus serum [corrected] in LIAISON assay). LIMITATIONS This is a cross-sectional study that used single lots of reagents. There currently is no reference method for the measurement of PTH and no recombinant PTH standard for PTH assay. CONCLUSION PTH variability caused by the nature of the assay and/or blood specimen type is large enough to potentially influence clinical decision making. A specified collection method therefore should be used for PTH measurements. In routine practice, we recommend serum PTH over EDTA or citrate plasma.
Collapse
Affiliation(s)
- Dominique Joly
- Service de Néphrologie, Laboratoire d'Explorations Fonctionnelles and Inserm Unit 845, Hôpital Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, Université Paris-Descartes, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Naumova NN, Schappert J, Kaplan LA. Patterns of add-on tests for hospitalized and for private patient populations. Arch Pathol Lab Med 2007; 131:1794-9. [PMID: 18081438 DOI: 10.5858/2007-131-1794-poatfh] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/14/2007] [Indexed: 11/06/2022]
Abstract
CONTEXT The policy of storing clinical samples in a pathology laboratory is based on long-standing practice rather than on objective data regarding the actual use of the stored samples. OBJECTIVE To determine the time after initial order that requests for add-on tests are submitted to the laboratory. These data might be useful for improving the efficiency of sample storage. DESIGN Two hundred sixteen add-on requests evenly divided between inpatients and private practice patients were reviewed for types of tests added on and the time of the requests. RESULTS Ninety-five percent of add-on test requests for inpatients were made by 0.75 day after the initial order (range, 0.01-4.3 days). However, the 95th percentile for private practice patients' add-on requests did not occur until 5.6 days later (range, 0.01-7.0 days). The pattern of add-on tests for hospitalized patients also differed from those for private practice patients. Most add-on tests for hospitalized patients were for routine hospital tests, and the private practice add-on requests were for assays that were not as routine, frequently for testing referred to the reference laboratory. This difference affected the rapidity of completing the add-on tests. CONCLUSIONS Samples for hospitalized patients can be stored for 3 days, but samples from patients in private practices should be held for 7 days. This change of "usual" storage practice would increase the efficient use of laboratory space and personnel. Screening all requests for add-on tests for hospitalized patients might reduce the frequency of unnecessary add-on requests, further increasing the efficiency of the laboratory.
Collapse
Affiliation(s)
- Nadia N Naumova
- Department of Pathology and Laboratory Medicine, Beth Israel Medical Center, New York, NY, USA
| | | | | |
Collapse
|
11
|
Cavalier E, Delanaye P, Carlisi A, Krzesinski JM, Chapelle JP. Stability of intact parathyroid hormone in samples from hemodialysis patients. Kidney Int 2007; 72:370-2. [PMID: 17554256 DOI: 10.1038/sj.ki.5002363] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The determination of intact parathyroid hormone levels is used for diagnosis and in the management of renal osteodystrophy. Pre-analytical and analytical conditions are important in the overall confidence of the assay. Unfortunately, there are no clear recommendations for the use of serum samples or samples anticoagulated with ethylenediaminotetraacetic acid (EDTA) for the best preservation of intact parathyroid hormone. In our study, the Roche Elecsys assay was used to measure intact hormone in both serum and EDTA plasmas from 16 hemodialysis patients over the span of a month. Parathyroid hormone stability was determined in samples kept frozen for 1-5 days or after 8-24 h at room temperature. There was no difference in hormone stability between serum and EDTA samples after 1 day in frozen storage. After 5 days frozen, hormone degradation was significantly greater after EDTA anticoagulation than in serum aliquots. When samples were stored at room temperature, intact parathyroid hormone was significantly more stable in EDTA-treated samples than in clotted serum samples, especially after 24 h. We conclude that optimum results are achieved in the measurement of intact parathyroid hormone levels depending on the workflow of the lab. If the lab works with intermittent batches of samples, frozen serum is the best. If the lab services general practitioners and/or several hospitals and has a continuous flow of samples, EDTA-treated samples stored at room temperature are the best.
Collapse
Affiliation(s)
- E Cavalier
- Department of Clinical Chemistry, University Hospital of Liege, University of Liege, Liege, Belgium.
| | | | | | | | | |
Collapse
|
12
|
Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006; 70:345-50. [PMID: 16788691 DOI: 10.1038/sj.ki.5001606] [Citation(s) in RCA: 184] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The National Kidney Foundation/Kidney-Dialysis Outcome Quality Initiative guidelines recommend to maintain the serum intact parathyroid hormone (PTH) concentration between 150 and 300 ng/l in chronic kidney disease (CKD) stage 5 patients. As these limits were derived from studies that used the Allegro intact PTH assay, we aimed to evaluate whether they were applicable to other PTH assays. We compared the PTH concentrations measured with 15 commercial immunoassays in 47 serum pools from dialysis patients, using the Allegro intact PTH assay as the reference. We also evaluated the recovery of graded amounts of synthetic 1-84 and 7-84 PTH added separately to a serum pool. Although the assays were highly correlated, the concentrations differed from one assay to another. The median bias between the tested assays and the Allegro intact PTH assay ranged from -44.9 to 123.0%. When the PTH concentrations were 150 or 300 ng/l with the Allegro intact PTH assay, they ranged with other assays from 83 to 323 ng/l and from 160 to 638 ng/l, respectively. The tested assays recognized 7-84 PTH with various cross-reactivities, whereas a given amount of 1-84 PTH was recovered differently by these assays. We found important inter-method variability in PTH results owing to both antibody specificity and standardization reasons. The unacceptable consequence is that opposite therapeutic attitudes may be reached in a single patient depending on the PTH assay used. We propose to use assay-specific decision limits for CKD patients, or to apply a correcting factor to the PTH results obtained with a given assay.
Collapse
|
13
|
Twomey PJ, Whitlock T, Pledger DR. Differences between serum and plasma for intact parathyroid hormone measurement in patients with chronic renal failure in routine clinical practice. J Clin Pathol 2005; 58:1000-1. [PMID: 16126890 PMCID: PMC1770825 DOI: 10.1136/jcp.2004.022186] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Parathyroid hormone (PTH) is important in the evaluation of patients with calcium metabolism disorders and/or chronic renal disease. AIMS To assess the differences between serum and plasma PTH measurements using the Advia Centaur. METHODS Twenty six paired serum and edetate samples from patients with chronic renal failure were analysed using the Advia Centaur. RESULTS The EDTA results ranged from 2.3 to 76.1 pmol/litre and the Deming regression equation was: serum = 0.8927 EDTA - 0.447. The percentage difference plot had a mean difference of 13.8% (95% confidence interval, 2.2% to 25.4%; significant). The available time to separation and freezing ranged from 10 to 231 (median, 85) minutes. The correlation coefficient for the percentage difference against the time to separation and the percentage difference against the mean PTH concentration were -0.13 and -0.07, respectively. CONCLUSIONS These results go beyond the previous controlled research conditions by showing that such differences between serum and edentate plasma exist in routine clinical practice. They also show that intra-individual PTH differences as large as 25.0% can exist on the same day between serum and edetate plasma. This may partly explain some of the variability of PTH concentrations found in some patients with chronic renal failure.
Collapse
Affiliation(s)
- P J Twomey
- Department of Clinical Biochemistry, Ipswich Hospital, Heath Road, Ipswich, Suffolk IP4 5PD, UK.
| | | | | |
Collapse
|
14
|
Holmes DT, Levin A, Forer B, Rosenberg F. Preanalytical influences on DPC IMMULITE 2000 intact PTH assays of plasma and serum from dialysis patients. Clin Chem 2005; 51:915-7. [PMID: 15855672 DOI: 10.1373/clinchem.2004.046821] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Daniel T Holmes
- Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Vancouver, Canada.
| | | | | | | |
Collapse
|
15
|
Teal TK, Wood JL, Stevens PE, Lamb EJ. Stability of Bio-Intact (1–84) Parathyroid Hormone ex Vivo in Serum and EDTA Plasma from Hemodialysis Patients. Clin Chem 2004; 50:1713-4. [PMID: 15331521 DOI: 10.1373/clinchem.2004.037994] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
16
|
Scharnhorst V, Valkenburg J, Vosters C, Vader H. Influence of Preanalytical Factors on the Immulite Intact Parathyroid Hormone Assay. Clin Chem 2004; 50:974-5. [PMID: 15105364 DOI: 10.1373/clinchem.2003.027912] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
17
|
Carter AB, Howanitz PJ. Intraoperative testing for parathyroid hormone: a comprehensive review of the use of the assay and the relevant literature. Arch Pathol Lab Med 2003; 127:1424-42. [PMID: 14567726 DOI: 10.5858/2003-127-1424-itfpha] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE The rapid intraoperative parathyroid hormone assay is transforming the parathyroidectomy procedure. We present a review of the literature on the use of the assay as an adjunct to surgery. To our knowledge, this is the first review of the literature to encompass and compare all known primary studies of this assay in parathyroidectomy patients. DATA SOURCES Articles were collected by searching MEDLINE databases using relevant terminology. The references of these articles were reviewed for additional studies. Supplementary articles pertinent to the parathyroidectomy procedure, preoperative parathyroid localization studies, and intraoperative parathyroid hormone assay development also were examined. STUDY SELECTION AND DATA EXTRACTION One hundred sixty-five references were analyzed and categorized separately into groups. DATA SYNTHESIS The primary studies of intraoperative data on patients undergoing parathyroidectomy were compared when possible. Studies were analyzed by type of assay used, where performed, turnaround time, and efficiency of use. Reviews of the types of parathyroid surgery and preoperative localization were included for educational purposes.Conclusions.-The intraoperative parathyroid hormone assay is a useful adjunct to preoperative imaging and parathyroid surgery because of its unique ability to detect an occult residuum of hyperfunctioning parathyroid tissue. Use of this assay will obviate the need for frozen section in most routine cases. The test facilitates minimally invasive parathyroidectomy for single parathyroid adenomas, which, in turn, improves cost-effectiveness and cosmetic outcome. Its use in patients with known preoperative multiglandular disease is promising but requires further study.
Collapse
Affiliation(s)
- Alexis Byrne Carter
- Department of Pathology & Laboratory Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
| | | |
Collapse
|
18
|
Glendenning P, Laffer LLA, Weber HK, Musk AA, Vasikaran SD. Parathyroid Hormone Is More Stable in EDTA Plasma Than in Serum. Clin Chem 2002. [DOI: 10.1093/clinchem/48.5.766] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Paul Glendenning
- Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth 6000, Western Australia
| | - Leonie L A Laffer
- Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth 6000, Western Australia
| | - Hayley K Weber
- Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth 6000, Western Australia
| | - Alexander A Musk
- Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth 6000, Western Australia
| | - Samuel D Vasikaran
- Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth 6000, Western Australia
| |
Collapse
|